1. Appelberg BG Syvalahti E Muhonen T Koskinen T Naukkarinen H Mehtonen OP Patients with severe depression may benefit from buspirone augmentation of selective SSRIs 153rd Annual Meeting of the American Psychiatric Association, 2000 May 13-18; Chicago (IL) 2000 NR470
2. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study;Appelberg;Journal of Clinical Psychiatry,2001
3. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study;Bauer;Journal of Clinical Psychiatry,2009
4. NCT00351910 A multi-centre, double-blind, randomised, parallel-group, placebo-controlled phase III study of the efficacy and safety of quetiapine fumarate sustained release (Seroquel SR TM ) in combination with an antidepressant in the treatment of patients with major depressive disorder with inadequate response to an antidepressant treatment clinicaltrials.gov/show/NCT00351910
5. Dunner D Amsterdam JD Shelton RC Loebel A Adjunctive ziprasidone for resistant depression: 8-week pilot study 45th Annual NCDEU (New Clinical Drug Evaluation Unit) Meeting; 2005 June 6 - 9; Boca Raton (FL) 2005 123